SAN FRANCISCO, Nov. 24, 2025 (GLOBE NEWSWIRE) -- Medical device manufacturer Inspire Medical Systems, Inc. (NYSE: INSP) is the subject of a securities class action lawsuit following a sharp decline in its stock price, with shareholders alleging the company misled investors about the launch of its latest product, the Inspire V device for obstructive sleep apnea. Hagens Berman is investigating the allegations. The firm urges investors in Inspire who suffered significant losses to submit your losses now. Class ...

Core Viewpoint - A class-action lawsuit has been filed against KBR, Inc. alleging misleading statements made by the company prior to the cancellation of a significant military contract, which adversely affected its business outlook [1][2]. Summary by Sections Legal Action - The lawsuit seeks to represent investors who acquired KBR securities between May 6, 2025, and June 19, 2025, with a deadline for lead plaintiffs set for November 18, 2025 [2]. - The legal action claims that KBR executives provided an overly optimistic outlook on a crucial partnership just before its collapse [2]. Contract Cancellation - The litigation arises from the U.S. Department of Defense's cancellation of its global household goods contract with HomeSafe Alliance LLC, a joint venture led by KBR, announced on June 20, 2025 [3]. - This cancellation resulted in a more than 7% drop in KBR's share price, reflecting investor concerns over the loss of a contract potentially worth up to $20 billion over nine years [3]. Misrepresentation Allegations - On May 6, 2025, during its Q1 earnings call, KBR assured investors that the HomeSafe partnership was "strong" and projected a revenue contribution of approximately $400 million for 2025 [4]. - However, on June 19, 2025, HomeSafe revealed that TRANSCOM had terminated the contract due to operational issues, which KBR allegedly knew about but did not disclose to investors [5]. Financial Impact - Following the contract termination, KBR revised its low-end 2025 revenue guidance downward by about $900 million, a decrease of 9%, primarily due to the removal of the HomeSafe JV revenue contribution [5]. - KBR management acknowledged operational challenges during the Q2 2025 earnings call, indicating a shift in the company's financial outlook [5].

Core Viewpoint - Inspire Medical Systems, Inc. is facing a proposed class-action lawsuit for allegedly misleading investors regarding the commercial readiness and demand for its Inspire V sleep apnea device, leading to a significant stock decline [1][6]. Company Overview - Inspire Medical Systems, Inc. is under investigation by prominent investor rights law firm Hagens Berman for claims related to investor losses during the class period from August 6, 2024, to August 4, 2025 [2][3]. Allegations and Claims - The lawsuit asserts that Inspire provided repeated assurances about meeting all regulatory and commercial prerequisites for the Inspire V launch, while claiming high demand and successful commercial proceedings [3]. - Contrary to these assurances, the lawsuit claims that the Inspire V launch was a failure, with minimal initial demand due to customers being overstocked with the older Inspire IV devices [4]. - The complaint indicates that Inspire neglected essential steps to facilitate the new device's adoption by clinicians and payors [4]. Impact of the Launch - On August 4, 2025, Inspire disclosed that the launch faced an "elongated timeframe" due to undisclosed challenges, including incomplete training and onboarding at many centers [5]. - The company noted that while the CPT code for Inspire V was approved for Medicare patients, necessary software updates for claims processing were delayed until July 1, affecting billing capabilities [5]. - Demand for Inspire V was further hindered by the need for customers to deplete existing Inspire IV inventory, which is expected to continue impacting demand [6]. Financial Consequences - Following the disastrous launch, Inspire slashed its 2025 earnings guidance by 80%, projecting earnings of only $0.40 to $0.50 per share [6]. - The announcement led to a significant drop in Inspire's stock price, with shares falling by approximately 32%, or $42.04, the day after the news [6].

Core Viewpoint - Inspire Medical Systems, Inc. is facing a proposed class-action lawsuit for allegedly misleading investors regarding the commercial readiness and demand for its Inspire V sleep apnea device, leading to a significant stock decline [1][6]. Company Overview - Inspire Medical Systems, Inc. is under investigation by prominent investor rights law firm Hagens Berman for claims related to investor losses during the class period from August 6, 2024, to August 4, 2025 [2][3]. Allegations of Misleading Information - The lawsuit claims that Inspire provided repeated assurances about meeting all regulatory and commercial prerequisites for the Inspire V launch while promoting high demand, which was later revealed to be untrue [3][4]. - The complaint highlights that the actual launch of Inspire V was disastrous, with minimal initial demand attributed to customers being overstocked with the older Inspire IV devices [4][5]. Impact of the Launch - On August 4, 2025, Inspire disclosed that the launch faced an "elongated timeframe" due to undisclosed challenges, including incomplete training and onboarding at implanting centers [5][6]. - The company noted that although the CPT code for Medicare patients was approved, software updates for claims processing did not take effect until July 1, delaying billing for procedures and leading centers to continue using the older Inspire IV [5][6]. Financial Consequences - As a result of the poor launch performance, Inspire slashed its 2025 earnings guidance by 80%, projecting earnings of only $0.40 to $0.50 per share [6]. - Following this announcement, Inspire's stock price plummeted by approximately 32%, dropping $42.04 the next day [6].

Accessibility StatementSkip Navigation Then, during Soleno's November 4, 2025 Q3 2025 earnings call, the company revealed that "we did see a disruption in our launch trajectory […] mostly in the form of a lower number of start forms and increase[d] discontinuations for non-serious adverse events." Back on August 15, 2025, short seller Scorpion Capital raised questions about Soleno's disclosures and made several observations regarding VYKATâ"¢ XR. SLNO Investors with Losses Encouraged to Contact Hagens Berma ...

Core Viewpoint - CarMax, Inc. has experienced a significant decline in share price following the announcement of CEO Bill Nash's termination and disappointing preliminary financial results for Q3 2026, indicating potential issues with the company's business model and growth prospects [1][2]. Financial Performance - CarMax forecasts a comparable store unit decrease of 8% - 12% and net EPS in the range of $0.18 - $0.36, which is below analysts' expectations of $0.69 [2]. - The company reported a year-over-year net EPS decline of 24%, with retail used unit sales falling by 5.4% and comparable store used unit sales decreasing by 6.3% [5]. - CarMax Auto Finance (CAF) revenue declined by 11.02% year-over-year, attributed to a $142 million loan loss provision, marking a nearly 40% sequential increase and approximately 24% year-over-year jump [6]. Legal Issues - A securities class action has been filed against CarMax, focusing on allegations that the company misled investors regarding its business model and growth prospects during the class period from June 20, 2025, to September 24, 2025 [3][4]. - The complaint claims that CarMax's positive Q1 2026 results were misleading, as they were influenced by consumers pulling forward car purchases to avoid tariffs [4]. - The investigation by Hagens Berman is centered on whether CarMax intentionally misled investors about the strength of its business model and the quality of its CAF portfolio [7].

Core Viewpoint - A class-action lawsuit has been filed against KBR, Inc. alleging misleading statements to investors prior to the cancellation of a significant military contract, which adversely affected the company's business outlook [1][5]. Group 1: Lawsuit Details - The lawsuit seeks to represent investors who acquired KBR securities between May 6, 2025, and June 19, 2025 [1][2]. - The legal action claims that KBR executives provided an overly optimistic outlook on a crucial partnership just before its collapse [2][5]. Group 2: Contract Cancellation Impact - The lawsuit is linked to the Department of Defense's cancellation of a global household goods contract with HomeSafe Alliance LLC, a joint venture led by KBR, announced on June 20, 2025 [3]. - Following the contract termination, KBR shares dropped over 7% due to the loss of a contract valued at up to $20 billion over a potential nine-year term [3][5]. Group 3: Misrepresentation Allegations - On May 6, 2025, during its Q1 earnings call, KBR assured investors that the HomeSafe partnership was "strong" and projected a mid-point revenue contribution of about $400 million for 2025 [4]. - Just weeks later, on June 19, 2025, HomeSafe disclosed the termination of the contract due to operational issues, which KBR allegedly knew about but did not disclose to investors [5]. Group 4: Financial Revisions - After the class period, KBR revised its low-end 2025 revenue guidance downward by approximately $900 million (-9%) due to the removal of the HomeSafe JV revenue contribution [6]. - KBR management acknowledged operational challenges during the Q2 2025 earnings call, raising questions about whether the company misled investors regarding the contract's status [6].

Core Insights - The article discusses the significant stock sale by Frank Bisignano, the former CEO of Fiserv, which coincided with a sharp decline in Fiserv's stock price following disappointing Q3 2025 financial results [1][2][4]. Company Actions - Frank Bisignano sold approximately 2.6 million shares of Fiserv for about $423 million between mid-May and late-July 2025, just before his appointment as Commissioner of the Social Security Administration [1]. - Following Bisignano's departure, Fiserv appointed Michael Lyons as the new CEO and Doyle Simmons as the non-executive Chairman [3]. Financial Performance - Fiserv reported a sequential decline in Q3 2025 adjusted revenue and reduced its organic revenue growth expectations to 3.5%-4% [4]. - The company also lowered its earnings per share (EPS) outlook to $8.50-$8.60 and announced the departure of its chief financial officer [4]. Market Reaction - The market reacted negatively to Fiserv's earnings report, causing the stock price to drop over $59, resulting in a loss of approximately $32 billion in shareholder value in one day [6]. - Analysts described the earnings miss and guidance cut as "difficult to comprehend" and labeled the Q3 results as "abysmal" [6]. Investigation - Hagens Berman has initiated an investigation into whether Fiserv misled investors regarding its business and growth prospects [2][6]. - The investigation is focused on the accuracy of Fiserv's statements about its operations and growth potential, particularly in light of the recent financial performance [3][6].

Core Viewpoint - Hagens Berman is investigating Stride, Inc. for potential violations of U.S. securities laws due to significant operational issues and fraud allegations that have led to a sharp decline in the company's stock price [1][4]. Group 1: Operational Issues - Stride reported Q1 earnings overshadowed by a major operational issue and cautious guidance, which triggered a sell-off in the stock [2]. - The company experienced significant disruptions while implementing an upgraded platform, resulting in an estimated loss of 10,000 to 15,000 enrollments, impacting its total enrollment of 247,700 [5]. - CEO James Rhyu acknowledged the implementation issues, stating that the poor customer experience led to higher withdrawal and lower conversion rates than expected [5]. Group 2: Financial Guidance - Stride's guidance for 2026 forecasts only 5% sales growth, a significant slowdown from the annualized sales growth of 19% over the past five years, raising concerns among investors [5]. Group 3: Fraud Allegations - Prior allegations against Stride include claims of fraud, deceptive practices, and prioritizing profits over student welfare, leading to a stock price drop of $18.60, or 11% [3]. - Allegations include artificially inflating student enrollment figures with "ghost students," increasing student-to-teacher ratios to boost profit margins, and employing insufficiently licensed teachers [6]. - The company is also accused of using unlawful practices to lower overhead costs to inflate stock values [6].

Core Insights - Fiserv, Inc. experienced a significant decline in share price, dropping over $59 (-47%) following the release of disappointing Q3 2025 financial results, which analysts described as "abysmal" [1][4][6] Financial Performance - The company reported a sequential decline in Q3 2025 adjusted revenue and reduced organic revenue growth expectations to 3.5%-4% [4] - Fiserv also lowered its earnings per share (EPS) outlook to $8.50-$8.60 [4] - The market reaction resulted in a loss of $32 billion in shareholder value in a single day [6] Management Changes - Following the poor financial results, Fiserv announced the departure of its chief financial officer and a shake-up in its board of directors, including the replacement of the non-executive Chairman and the head of the audit committee, effective January 1, 2026 [4][5] Investigation - Hagens Berman, a national shareholders rights firm, has initiated an investigation into whether Fiserv misled investors regarding its financial performance and growth prospects [2][6] - The investigation is focused on the propriety of Fiserv's statements about its business and growth expectations [3][6] Leadership Insights - The new CEO, Michael Lyons, indicated that a rigorous analysis of the company's operations led to a recalibration of previously optimistic growth assumptions set by prior leadership [5] - Lyons emphasized that several initiatives were found to be "short-term driven," prompting dissatisfaction with existing processes and subsequent leadership changes [5]